ATE319449T1 - Dosierschema für ppar-gamma-aktivatoren - Google Patents

Dosierschema für ppar-gamma-aktivatoren

Info

Publication number
ATE319449T1
ATE319449T1 AT02805961T AT02805961T ATE319449T1 AT E319449 T1 ATE319449 T1 AT E319449T1 AT 02805961 T AT02805961 T AT 02805961T AT 02805961 T AT02805961 T AT 02805961T AT E319449 T1 ATE319449 T1 AT E319449T1
Authority
AT
Austria
Prior art keywords
ppar
dosage scheme
gamma
gamma activators
administration
Prior art date
Application number
AT02805961T
Other languages
English (en)
Inventor
Kathleen Keating Brown
Philip G Baer
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE319449T1 publication Critical patent/ATE319449T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02805961T 2001-12-21 2002-12-18 Dosierschema für ppar-gamma-aktivatoren ATE319449T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34515301P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
ATE319449T1 true ATE319449T1 (de) 2006-03-15

Family

ID=23353763

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02805961T ATE319449T1 (de) 2001-12-21 2002-12-18 Dosierschema für ppar-gamma-aktivatoren

Country Status (8)

Country Link
US (1) US20050107450A1 (de)
EP (1) EP1465627B1 (de)
JP (1) JP2005514399A (de)
AT (1) ATE319449T1 (de)
AU (1) AU2002367154A1 (de)
DE (1) DE60209824T2 (de)
ES (1) ES2259736T3 (de)
WO (1) WO2003055485A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061041A1 (es) * 2005-01-28 2006-10-12 Lilly Co Eli Formulaciones y regimen de dosificacion para moduladores alfa de ppar
EP2155187B1 (de) * 2007-05-07 2016-05-25 Merck Sharp & Dohme Corp. Behandlungsverfahren unter verwendung fusionierter aromatischer verbindungen mit antidiabetischer wirkung
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
EP4194001B1 (de) 2015-04-22 2026-03-18 Cedars-Sinai Medical Center Enterisch verabreichte bittere oligopeptide zur behandlung von typ-2-diabetes und fettleibigkeit
MX379710B (es) 2016-12-01 2025-03-11 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.
US20180153860A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
SI1133312T1 (sl) * 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina

Also Published As

Publication number Publication date
AU2002367154A1 (en) 2003-07-15
DE60209824T2 (de) 2006-10-19
EP1465627A1 (de) 2004-10-13
US20050107450A1 (en) 2005-05-19
JP2005514399A (ja) 2005-05-19
ES2259736T3 (es) 2006-10-16
EP1465627B1 (de) 2006-03-08
DE60209824D1 (de) 2006-05-04
WO2003055485A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
BR0212203A (pt) Composições e processos para tratamento de diabetes
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
PT1112275E (pt) Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
PT1282611E (pt) Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase
TWI345978B (en) Combination therapy comprising glucose reabsorption inhibitors and retinoid x receptor modulators
EA200700934A1 (ru) Производные пиримидина и их применение в качестве модуляторов cb2
MXPA02011458A (es) Derivados de acilfenilurea, metodos para su produccion y uso de los mismos como farmacos.
MXPA03010232A (es) Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
DE69941435D1 (de) Monoclonaler anti-heparanase antikörper zur neutralisierung der heparanaseaktivität
BR0317494A (pt) Pré-polìmeros de poliuretano bloqueados com cetonas cìclicas ch-ácidas, sistemas reativos preparados a partir dos mesmo, sua preparação e aplicação
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
LT2004074A (en) Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti
ATE420099T1 (de) Medikament zur wachstumsinhibierung von tumoren
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
CY1113959T1 (el) Χρηση λιποσωματων pvp-ιωδιου για θεραπεια ακμης
DE602005026276D1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
DE602004031954D1 (de) Verbindungen zur behandlung von stoffwechselstörungen
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
ATE358501T1 (de) Zubereitung für die wundheilung und zur verhinderung des anhaftens von verbänden an die wunde
DE60209824D1 (de) Dosierschema für ppar-gamma-aktivatoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties